Skip to main content
. 2018 Jun 15;45(9):1053–1062. doi: 10.1111/1346-8138.14504

Figure 3.

Figure 3

Efficacy outcomes through week 52. (a) Proportion of patients achieving IGA 0/1. (b) Proportion of patients achieving IGA 0. (c) Proportion of patients achieving PASI‐75. (d) Proportion of patients achieving PASI‐90. (e) Proportion of patients achieving PASI‐100. *P < 0.001 for guselkumab versus placebo. IGA 0/1, Investigator Global Assessment score of cleared (0) or minimal (1); IGA 0, Investigator Global Assessment score of 0 (cleared); PASI‐75, 75% or more improvement in Psoriasis Area and Severity Index score from baseline; PASI‐90, 90% or more improvement in Psoriasis Area and Severity Index score from baseline; PASI‐100, 100% improvement in Psoriasis Area and Severity Index score from baseline.